Polyphosphate is a novel cofactor for regulation of complement by a serpin, C1 inhibitor

Blood

Volumn 128, Issue 13, 2016, Pages 1766-1776

  Wijeyewickrema, Lakshmi C ^a   Lameignere, Emilie ^b   Hor, Lilian ^a   Duncan, Renee C ^a   Shiba, Toshikazu ^c   Travers, Richard J ^d   Kapopara, Piyushkumar R ^b   Lei, Victor ^b   Smith, Stephanie A ^d   Kim, Hugh ^b,e   Morrissey, James H ^d   Pike, Robert N ^a   Conway, Edward M ^b  

^a LA TROBE UNIVERSITY   (Australia)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c Regenetiss Inc   (Japan)

^d UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^e UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CLASSICAL COMPLEMENT PATHWAY C3 C5 CONVERTASE; COMPLEMENT COMPONENT C1R; COMPLEMENT COMPONENT C1S; COMPLEMENT COMPONENT C2; COMPLEMENT COMPONENT C4D; HEPARIN; LECTIN; POLYPHOSPHATE; PROTEINASE; SERINE PROTEINASE; SERINE PROTEINASE INHIBITOR; COMPLEMENT; COMPLEMENT COMPONENT C1S INHIBITOR; COMPLEMENT COMPONENT C4; SERPING1 PROTEIN, HUMAN;

ARTICLE; CELL CULTURE; COMPLEMENT ACTIVATION; COMPLEX FORMATION; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME ACTIVITY; ENZYME KINETICS; FLOW CYTOMETRY; HUMAN; IMMUNOLOCALIZATION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN CLEAVAGE; PROTEIN LOCALIZATION; STOICHIOMETRY; SURFACE PLASMON RESONANCE; THROMBOCYTE; THROMBOCYTE ACTIVATION; BINDING SITE; CHEMISTRY; COMPLEMENT CLASSICAL PATHWAY; IMMUNOLOGY; IN VITRO STUDY; METABOLISM;

BINDING SITES; BLOOD PLATELETS; CELLS, CULTURED; COMPLEMENT C1 INACTIVATOR PROTEINS; COMPLEMENT C1S; COMPLEMENT C2; COMPLEMENT C4; COMPLEMENT PATHWAY, CLASSICAL; COMPLEMENT SYSTEM PROTEINS; ENDOTHELIAL CELLS; HEPARIN; HUMANS; IN VITRO TECHNIQUES; POLYPHOSPHATES;

EID: 84990053118     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2016-02-699561     Document Type: Article

References (71)

1. Ziccardi RJ. Activation of the early components of the classical complement pathway under physiologic conditions. J Immunol. 1981;126(5): 1769-1773.
2. Rossi V, Cseh S, Bally I, Thielens NM, Jensenius JC, Arlaud GJ. Substrate specificities of recombinant mannan-binding lectin-associated serine proteases-1 and -2. J Biol Chem. 2001; 276(44):40880-40887.
3. Wuillemin WA, Eldering E, Citarella F, de Ruig CP, ten Cate H, Hack CE. Modulation of contact system proteases by glycosaminoglycans. Selective enhancement of the inhibition of factor XIa. J Biol Chem. 1996;271(22):12913-12918.
4. Wuillemin WA, Minnema M, Meijers JC, et al. Inactivation of factor XIa in human plasma assessed by measuring factor XIa-protease inhibitor complexes: major role for C1-inhibitor. Blood. 1995;85(6):1517-1526.
5. de Agostini A, Lijnen HR, Pixley RA, Colman RW, Schapira M. Inactivation of factor XII active fragment in normal plasma. Predominant role of C-1-inhibitor. J Clin Invest. 1984;73(6):1542-1549.
6. Schapira M, Scott CF, Colman RW. Contribution of plasma protease inhibitors to the inactivation of kallikrein in plasma. J Clin Invest. 1982;69(2): 462-468.
7. Schmaier AH. Physiologic activities of the contact activation system. Thromb Res. 2014; 133(suppl 1):S41-S44.
8. Ghebrehiwet B, Randazzo BP, Dunn JT, Silverberg M, Kaplan AP. Mechanisms of activation of the classical pathway of complement by Hageman factor fragment. J Clin Invest. 1983; 71(5):1450-1456.
9. Caccia S, Suffritti C, Cicardi M. Pathophysiology of hereditary angioedema. Pediatr Allergy Immunol Pulmonol. 2014;27(4):159-163.
10. Ennis S, Jomary C, Mullins R, et al. Association between the SERPING1 gene and age-related macular degeneration: a two-stage case-control study. Lancet. 2008;372(9652):1828-1834.
11. Zeerleder S. C1-inhibitor: more than a serine protease inhibitor. Semin Thromb Hemost. 2011; 37(4):362-374.
12. Li HH, Moldovan D, Bernstein JA, et al. Recombinant human-C1 inhibitor is effective and safe for repeat hereditary angioedema attacks. J Allergy Clin Immunol Pract. 2015;3(3):417-423.
13. Wu MA, Zanichelli A, Mansi M, Cicardi M. Current treatment options for hereditary angioedema due to C1 inhibitor deficiency. Expert Opin Pharmacother. 2016;17(1):27-40.
14. Singer M, Jones AM. Bench-to-bedside review: the role of C1-esterase inhibitor in sepsis and other critical illnesses. Crit Care. 2011;15(1):203.
15. Vo AA, Zeevi A, Choi J, et al. A phase I/II placebocontrolled trial of C1-inhibitor for prevention of antibody-mediated rejection in HLA sensitized patients. Transplantation. 2015;99(2):299-308.
16. Schmaier AH, Murray SC, Heda GD, et al. Synthesis and expression of C1 inhibitor by human umbilical vein endothelial cells. J Biol Chem. 1989;264(30):18173-18179.
17. Bensa JC, Reboul A, Colomb MG. Biosynthesis in vitro of complement subcomponents C1q, C1s and C1 inhibitor by resting and stimulated human monocytes. Biochem J. 1983;216(2):385-392.
18. Schmaier AH, Smith PM, Colman RW. Platelet C1- inhibitor. A secreted alpha-granule protein. J Clin Invest. 1985;75(1):242-250.
19. Endresen GK. Immunological studies of plasma protease inhibitors associated with human blood platelets. Thromb Res. 1980;19(1-2):157-163.
20. Olson ST, Richard B, Izaguirre G, Schedin-Weiss S, Gettins PG. Molecular mechanisms of antithrombin-heparin regulation of blood clotting proteinases. A paradigm for understanding proteinase regulation by serpin family protein proteinase inhibitors. Biochimie. 2010;92(11):1587-1596.
21. Paréj K, Dobó J, Závodszky P, Gál P. The control of the complement lectin pathway activation revisited: both C1-inhibitor and antithrombin are likely physiological inhibitors, while a2- macroglobulin is not. Mol Immunol. 2013;54(3-4): 415-422.
22. Beinrohr L, Murray-Rust TA, Dyksterhuis L, et al. Serpins and the complement system. Methods Enzymol. 2011;499:55-75.
23. Kerr FK, Thomas AR, Wijeyewickrema LC, et al. Elucidation of the substrate specificity of the MASP-2 protease of the lectin complement pathway and identification of the enzyme as a major physiological target of the serpin, C1- inhibitor. Mol Immunol. 2008;45(3):670-677.
24. Murray-Rust TA, Kerr FK, Thomas AR, et al. Modulation of the proteolytic activity of the complement protease C1s by polyanions: implications for polyanion-mediated acceleration of interaction between C1s and SERPING1. Biochem J. 2009;422(2):295-303.
25. Wuillemin WA, te Velthuis H, Lubbers YT, de Ruig CP, Eldering E, Hack CE. Potentiation of C1 inhibitor by glycosaminoglycans: dextran sulfate species are effective inhibitors of in vitro complement activation in plasma. J Immunol. 1997;159(4):1953-1960.
26. Rajabi M, Struble E, Zhou Z, Karnaukhova E. Potentiation of C1-esterase inhibitor by heparin and interactions with C1s protease as assessed by surface plasmon resonance. Biochim Biophys Acta. 2012;1820(1):56-63.
27. Pixley RA, Schmaier A, Colman RW. Effect of negatively charged activating compounds on inactivation of factor XIIa by Cl inhibitor. Arch Biochem Biophys. 1987;256(2):490-498.
28. Kornberg A, Rao NN, Ault-Riché D. Inorganic polyphosphate: a molecule of many functions. Annu Rev Biochem. 1999;68:89-125.
29. Brown MR, Kornberg A. The long and short of it - polyphosphate, PPK and bacterial survival. Trends Biochem Sci. 2008;33(6):284-290.
30. Ruiz FA, Lea CR, Oldfield E, Docampo R. Human platelet dense granules contain polyphosphate and are similar to acidocalcisomes of bacteria and unicellular eukaryotes. J Biol Chem. 2004; 279(43):44250-44257.
31. Müller F, Mutch NJ, Schenk WA, et al. Platelet polyphosphates are proinflammatory and procoagulant mediators in vivo. Cell. 2009;139(6): 1143-1156.
32. Moreno-Sanchez D, Hernandez-Ruiz L, Ruiz FA, Docampo R. Polyphosphate is a novel proinflammatory regulator of mast cells and is located in acidocalcisomes. J Biol Chem. 2012;287(34): 28435-28444.
33. Smith SA, Mutch NJ, Baskar D, Rohloff P, Docampo R, Morrissey JH. Polyphosphate modulates blood coagulation and fibrinolysis. Proc Natl Acad Sci USA. 2006;103(4):903-908.
34. Smith SA, Morrissey JH. Polyphosphate enhances fibrin clot structure. Blood. 2008;112(7): 2810-2816.
35. Smith SA, Choi SH, Davis-Harrison R, et al. Polyphosphate exerts differential effects on blood clotting, depending on polymer size [published correction appears in Blood. 2011;117(12):3477]. Blood. 2010;116(20):4353-4359.
36. Smith SA, Morrissey JH. Polyphosphate: a new player in the field of hemostasis. Curr Opin Hematol. 2014;21(5):388-394.
37. Travers RJ, Smith SA, Morrissey JH. Polyphosphate, platelets, and coagulation. Int J Lab Hematol. 2015;37(suppl 1):31-35.
38. Wat JM, Foley JH, Krisinger MJ, et al. Polyphosphate suppresses complement via the terminal pathway. Blood. 2014;123(5):768-776.
39. Lennick M, Brew SA, Ingham KC. Kinetics of interaction of C1 inhibitor with complement C1s. Biochemistry. 1986;25(13):3890-3898.
40. McRae BJ, Lin TY, Powers JC. Mapping the substrate binding site of human C1r and C1s with peptide thioesters. Development of new sensitive substrates. J Biol Chem. 1981;256(23): 12362-12366.
41. Eldering E, Huijbregts CC, Lubbers YT, Longstaff C, Hack CE. Characterization of recombinant C1 inhibitor P1 variants. J Biol Chem. 1992;267(10): 7013-7020.
42. Morrison JF, Walsh CT. The behavior and significance of slow-binding enzyme inhibitors. Adv Enzymol Relat Areas Mol Biol. 1988;61: 201-301.
43. Ades EW, Candal FJ, Swerlick RA, et al. HMEC-1: establishment of an immortalized human microvascular endothelial cell line. J Invest Dermatol. 1992;99(6):683-690.
44. Kim H, Falet H, Hoffmeister KM, Hartwig JH. Wiskott-Aldrich syndrome protein (WASp) controls the delivery of platelet transforming growth factor-b1. J Biol Chem. 2013;288(48): 34352-34363.
45. Werner TP, Amrhein N, Freimoser FM. Specific localization of inorganic polyphosphate (poly P) in fungal cell walls by selective extraction and immunohistochemistry. Fungal Genet Biol. 2007; 44(9):845-852.
46. Duncan RC, Mohlin F, Taleski D, et al. Identification of a catalytic exosite for complement component C4 on the serine protease domain of C1s. J Immunol. 2012;189(5):2365-2373.
47. Perry AJ, Wijeyewickrema LC, Wilmann PG, et al. A molecular switch governs the interaction between the human complement protease C1s and its substrate, complement C4. J Biol Chem. 2013;288(22):15821-15829.
48. Choi SH, Collins JN, Smith SA, Davis-Harrison RL, Rienstra CM, Morrissey JH. Phosphoramidate end labeling of inorganic polyphosphates: facile manipulation of polyphosphate for investigating and modulating its biological activities. Biochemistry. 2010;49(45):9935-9941.
49. Rossi V, Bally I, Ancelet S, et al. Functional characterization of the recombinant human C1 inhibitor serpin domain: insights into heparin binding. J Immunol. 2010;184(9):4982-4989.
50. Wurst H, Shiba T, Kornberg A. The gene for a major exopolyphosphatase of Saccharomyces cerevisiae. J Bacteriol. 1995;177(4):898-906.
51. Sim RB, Arlaud GJ, Colomb MG. C1 inhibitordependent dissociation of human complement component C1 bound to immune complexes. Biochem J. 1979;179(3):449-457.
52. Rent R, Ertel N, Eisenstein R, Gewurz H. Complement activation by interaction of polyanions and polycations. I. Heparin-protamine induced consumption of complement. J Immunol. 1975;114(1 pt 1):120-124.
53. Beinrohr L, Harmat V, Dobó J, Lörincz Z, Gál P, Závodszky P. C1 inhibitor serpin domain structure reveals the likely mechanism of heparin potentiation and conformational disease. J Biol Chem. 2007;282(29):21100-21109.
54. Sim RB, Arlaud GJ, Colomb MG. Kinetics of reaction of human C1-inhibitor with the human complement system proteases C1r and C1s. Biochim Biophys Acta. 1980;612(2):433-449.
55. de Agostini A, Patston PA, Marottoli V, Carrel S, Harpel PC, Schapira M. A common neoepitope is created when the reactive center of C1-inhibitor is cleaved by plasma kallikrein, activated factor XII fragment, C1 esterase, or neutrophil elastase. J Clin Invest. 1988;82(2):700-705.
56. Dobó J, Harmat V, Beinrohr L, Sebestyén E, Závodszky P, Gál P. MASP-1, a promiscuous complement protease: structure of its catalytic region reveals the basis of its broad specificity. J Immunol. 2009;183(2):1207-1214.
57. Schröder HC, Kurz L, Müller WE, Lorenz B. Polyphosphate in bone. Biochemistry (Mosc). 2000;65(3):296-303.
58. Brandt S, Krauel K, Jaax M, et al. Polyphosphates form antigenic complexes with platelet factor 4 (PF4) and enhance PF4-binding to bacteria. Thromb Haemost. 2015;114(6):1189-1198.
59. Heijnen H, van der Sluijs P. Platelet secretory behaviour: as diverse as the granules ... or not? J Thromb Haemost. 2015;13(12):2141-2151.
60. Golebiewska EM, Poole AW. Platelet secretion: from haemostasis to wound healing and beyond. Blood Rev. 2015;29(3):153-162.
61. Hurford MT, Sebastiano C. Hermansky-Pudlak syndrome: report of a case and review of the literature. Int J Clin Exp Pathol. 2008;1(6): 550-554.
62. Hernández-Ruiz L, Sáez-Benito A, Pujol-Moix N, Rodríguez-Martorell J, Ruiz FA. Platelet inorganic polyphosphate decreases in patients with delta storage pool disease. J Thromb Haemost. 2009; 7(2):361-363.
63. Dinarvand P, Hassanian SM, Qureshi SH, et al. Polyphosphate amplifies proinflammatory responses of nuclear proteins through interaction with receptor for advanced glycation end products and P2Y1 purinergic receptor. Blood. 2014;123(6):935-945.
64. Hassanian SM, Dinarvand P, Smith SA, Rezaie AR. Inorganic polyphosphate elicits pro-inflammatory responses through activation of the mammalian target of rapamycin complexes 1 and 2 in vascular endothelial cells. J Thromb Haemost. 2015;13(5): 860-871.
65. Davis AE III, Cai S, Liu D. C1 inhibitor: biologic activities that are independent of protease inhibition. Immunobiology. 2007;212(4-5): 313-323.
66. Davis AE III, Mejia P, Lu F. Biological activities of C1 inhibitor. Mol Immunol. 2008;45(16): 4057-4063.
67. Patston PA, Schapira M. Regulation of C1- inhibitor function by binding to type IV collagen and heparin. Biochem Biophys Res Commun. 1997;230(3):597-601.
68. Cai S, Dole VS, Bergmeier W, et al. A direct role for C1 inhibitor in regulation of leukocyte adhesion. J Immunol. 2005;174(10): 6462-6466.
69. Liu D, Lu F, Qin G, Fernandes SM, Li J, Davis AE III. C1 inhibitor-mediated protection from sepsis. J Immunol. 2007;179(6):3966-3972.
70. Berger M, Baldwin WM III, Jordan SC. Potential roles for C1 inhibitor in transplantation. Transplantation. 2016;100(7):1415-1424.
71. Wouters D, Wagenaar-Bos I, van Ham M, Zeerleder S. C1 inhibitor: just a serine protease inhibitor? New and old considerations on therapeutic applications of C1 inhibitor. Expert Opin Biol Ther. 2008;8(8): 1225-1240.